Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

BioCryst reports on phase IIa trial of BCX-4208 in patients with gout

April 29, 2010

Phase II data presented on pasireotide in Cushing's disease and acromegaly

April 29, 2010

Living Cell Technologies receives grant from JDRF for phase II DiabeCell trial

April 28, 2010

Santaris advances SPC-5001 into development to lower cholesterol

April 28, 2010

No endocrine safety concerns noted in phase II trials of ulipristal acetate for uterine fibroids

April 28, 2010

Greater HbA1c reductions with LY-2189265 in Hispanic patients with type 2 diabetes

April 28, 2010

GlaxoSmithKline presents new calcium receptor antagonists

April 27, 2010

GSK discloses new calcium-sensing receptor antagonists

April 26, 2010

Amylin, Lilly and Alkermes reply to FDA's complete response letter on Bydureon

April 23, 2010

Nuon advances NU-1618 to phase IIb for chronic hyperuricemia in gout

April 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...